Emmaus Life Sciences, Inc.
EMMAOTCHealthcare● Active
$0.01
$-0.00(-4.95%)
Market Cap$673807
P/E Ratio—
52W High$0.0175
52W Low$0.008
Emmaus Life Sciences, Inc. (EMMA) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · EMMA · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $12.45M | $16.65M | $29.60M | $18.39M | $20.61M |
| Cost of Revenue | $0.86M | $1.20M | $1.34M | $2.59M | $3.31M |
| Gross Profit | $11.60M | $15.45M | $28.25M | $15.80M | $17.30M |
| Gross Margin %(computed) | 93.12% | 92.79% | 95.47% | 85.93% | 83.93% |
| Operating Expenses | |||||
| R&D Expenses | $0.31M | $0.66M | $1.19M | $1.73M | $4.11M |
| G&A Expenses | $8.18M | $10.69M | $14.89M | $13.17M | $13.44M |
| Total Operating Expenses | $11.37M | $17.35M | $24.71M | $22.39M | $23.43M |
| Operating Income | $0.23M | ($1.89M) | $3.54M | ($6.59M) | ($6.13M) |
| Operating Margin %(computed) | 1.85% | -11.37% | 11.96% | -35.81% | -29.73% |
| Interest Income | $0.27M | $0.27M | $0.68M | $0.68M | $0.76M |
| Interest Expense | $7.13M | $5.49M | $7.38M | $5.01M | $3.10M |
| Income Before Tax | ($7.48M) | ($6.42M) | ($3.79M) | ($10.56M) | ($15.92M) |
| Income Tax Expense | $0.01M | $0.03M | ($0.06M) | $0.06M | $0.03M |
| Net Income | ($7.49M) | ($6.45M) | ($3.73M) | ($10.63M) | ($15.95M) |
| Net Margin %(computed) | -60.16% | -38.75% | -12.61% | -57.78% | -77.37% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.12 | $-0.10 | $-0.07 | $-0.21 | $-0.32 |
| Wtd Avg Shares | 64.04M | 63.23M | 53.10M | 49.44M | 49.25M |
| EBITDA | ($0.31M) | ($0.91M) | $3.62M | ($5.50M) | ($12.76M) |
| EBITDA Margin %(computed) | -2.49% | -5.46% | 12.24% | -29.90% | -61.92% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Emmaus Life Sciences, Inc. data
About Emmaus Life Sciences, Inc. (EMMA) Income Statement
Emmaus Life Sciences, Inc. (EMMA) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, EMMA reported revenue of $0.01B, gross profit of $0.01B (gross margin 93.12%), and net income of ($0.01B) — a net profit margin of -60.16%.
Frequently asked questions
EMMA · 4 questionsEmmaus Life Sciences, Inc. (EMMA) reported revenue of $0.01B for 2025, down 25.2% year-over-year.
EMMA revenueEMMA salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09